IDEAYA Biosciences (IDYA) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026Pipeline and 2026 milestones
2026 brought the first NDA filing, darovasertib Phase III top-line results presented at ASCO, and positive second-line SCLC OS data for the DLL3 TOP1 ADC at ESMO.
DLL3 TOP1 ADC advanced into Phase III registrational studies; MTAP and CDKN2A programs were slated for discussion at the London R&D event.
Darovasertib in metastatic uveal melanoma
NDA filed in late Q3 under RTOR; filing strategy seeks use irrespective of HLA-A2 status, subject to FDA review. NCCN plans cover HLA-A2-negative and -positive populations.
HLA-A2-negative patients were estimated at 60% to two-thirds of the population; >95% of patients were believed to have activating GNAQ/11 mutations, supporting an HLA-independent mechanism rationale.
PFS is considered sufficient for accelerated approval based on FDA-aligned endpoints; interim OS readout remained guided for mid-2027, with OS intended as confirmatory evidence.
A strong launch was anticipated based on first-line use, no GNAQ/11 diagnostic requirement, and reported PFS hazard ratio and response rate approximately six times the control arm.
NCCN guideline process expected to start close to approval and take several months; a 2027 review was considered possible given high unmet need.
PRMT5 and MTAP strategy
Clinical data planned for later that day included human PK, safety, pharmacodynamic data, and patient case studies; a potential best-in-class profile was tied to a clean CYP3A4 DDI profile, limited CNS penetration, and MTA-cooperative selective binding.
Early clinical combination data with IDE397, another CYP3A4-mediated molecule, were cited as supporting a favorable DDI profile; first dosing with Roche pan-RAS was expected by year-end 2026.
Clinical data update targeted for 2027; the initial pan-RAS combination cohort could use the expansion dose, with potentially one cohort and anticipated meaningful activity.
Pancreatic cancer was the top combination priority, with frontline PDAC viewed as an open opportunity; the relevant population was estimated at 40%. Lung cancer was also a potential target, with the co-alteration subset estimated at ~5%.
CDKN2A candidate IDE101 was expected to enter clinical testing in H1 2027.
Latest events from IDEAYA Biosciences
- Darovasertib advances toward launch as oncology pipeline catalysts build through 2027.IDYA
Jefferies Global Healthcare Conference - Early responses support a combination-led pipeline with multiple 2027 catalysts.IDYA
R&D Day 2026 - Darovasertib mUM NDA filed; Q3 net loss was $125.749M with $1.15B in liquidity.IDYA
Q3 2026 - Darovasertib nears NDA, while DLL3 ADC and MTAP/KRAS programs drive pipeline innovation.IDYA
Morgan Stanley 24th Annual Global Healthcare Conference - NDA submission and commercial launch for a late-stage oncology asset are on track; key data updates expected this year.IDYA
Citigroup’s Biopharma Back to School Summit 2026 - Darovasertib NDA nears completion as pipeline expands with DLL3 ADC, PRMT5, and Roche collaborations.IDYA
12th Annual Cantor Fitzgerald Global Healthcare Conference - Darovasertib and DLL3 programs advance toward key regulatory and clinical milestones.IDYA
Wells Fargo 21st Annual Healthcare Conference - Precision oncology pipeline delivers clinical advances in UM and solid tumors, with strong cash runway.IDYA
Corporate presentation - Net loss widened to $211M in H1 2026 as R&D spending rose, with $1.24B in cash reserves.IDYA
Q2 2026